Home
Profile
Manufacturing
Quality Control
Products
  Contact Us Careers Sitemap          
   
 
:: Research & Development
:: International Collaboration
:: Business Opportunities
:: Latest Events
:: Divisions At a Glance


  press_release_btn_otherspg :: Press Releases vline_separator

  :: In Licensing   inlicensing_btn__otherspg vline_separator

  outlicensing_btn_otherspg :: Out Licensing vline_separator

 
  Cyclophosphamide for Injection USP 200 mg
  Indications :
 

Malignant Disease :

Malignant lymphomas (Stages III and IV of the Ann Arbor staging system).

Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), Mixed-cell type lymphoma.

Histiocytic lymphoma.

Burkitt's lymphoma.

Multiple myeloma.


Leukemias :

Chronic lymphocytic leukemia

Chronic granulocytic leukemia.

Acute myelogenous & monocytic leukemia.

Acute lymphoblastic (stem cell) leukemia in children (given during remission is effective in prolonging its duration).

Mycosis fungoides (advanced disease).

Neuroblastoma (disseminated disease).

Adenocarcinoma of the ovary.

Retinoblastoma.

Carcinoma of the breast.

   
  Dosage :
  ADULTS AND CHILDREN :

Single oncolytic drug therapy
: 40 to 50 mg/kg IV in divided doses over a period of 2 to 5 days.

Other intravenous regimens included : 10 to 15 mg/kg given every 7 to 10 days or 3 to 5 mg/kg twice weekly.

General Intravenous Dosage : 40-50 mg/kg intravenously in divided doses over a period of 2-5 days.

Dosage Adjustment :

Renal Impairment : Required.

Hepatic Impairment : Not required.
   
  Packing : 10 Vials of 200 mg
 



  Home | Careers | Site map | Contact Us



 
  All contents copyright © United Biotech (P) Limited, All rights reserved.